NEIL2

Across TCGA pan-cancer cohorts, NEIL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NEIL2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NEIL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NEIL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, LSCC, and GBM are the cancer types where NEIL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.834	0.460	.015	18	view →
LSCC	DFS	Median	II,III,IV	0.844	0.973	.014	12	view →
GBM	DFS	Median	All	0.461	0.289	.018	9	view →
CCRCC	OS	Median	II,III,IV	0.571	1.000	.014	7	view →
HNSC	DFS	Tertile	II,III,IV	0.937	1.000	.042	3	view →
PDAC	DFS	Median	All	0.452	0.283	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NEIL2–LUAD (DFS)

Open the LUAD breakdown →